206 related articles for article (PubMed ID: 29454314)
1. A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
de Fonseka D; Arnold DT; Stadon L; Morley A; Keenan E; Darby M; Armstrong L; Virgo P; Maskell NA
BMC Cancer; 2018 Feb; 18(1):199. PubMed ID: 29454314
[TBL] [Abstract][Full Text] [Related]
2. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.
Hooper CE; Lyburn ID; Searle J; Darby M; Hall T; Hall D; Morley A; White P; Rahman NM; De Winton E; Clive A; Masani V; Arnold DT; Dangoor A; Guglani S; Jankowska P; Lowndes SA; Harvey JE; Braybrooke JP; Maskell NA
Br J Cancer; 2015 Mar; 112(7):1175-82. PubMed ID: 25756396
[TBL] [Abstract][Full Text] [Related]
3. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice.
Linch M; Gennatas S; Kazikin S; Iqbal J; Gunapala R; Priest K; Severn J; Norton A; Ayite B; Bhosle J; O'Brien M; Popat S
BMC Cancer; 2014 Sep; 14():674. PubMed ID: 25227779
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
5. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
6. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
[TBL] [Abstract][Full Text] [Related]
8. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
[TBL] [Abstract][Full Text] [Related]
9. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
[TBL] [Abstract][Full Text] [Related]
10. The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.
Arnold DT; Hooper CE; Morley A; White P; Lyburn ID; Searle J; Darby M; Hall T; Hall D; Rahman NM; De Winton E; Clive A; Masani V; Dangoor A; Guglani S; Jankowska P; Lowndes SA; Harvey JE; Braybrooke JP; Maskell NA
Br J Cancer; 2015 Mar; 112(7):1183-9. PubMed ID: 25756395
[TBL] [Abstract][Full Text] [Related]
11. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK
Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
17. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
Tsim S; Kelly C; Alexander L; McCormick C; Thomson F; Woodward R; Foster JE; Stobo DB; Paul J; Maskell NA; Chalmers A; Blyth KG
BMJ Open; 2016 Nov; 6(11):e013324. PubMed ID: 27884852
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers.
Bogar F; Ak G; Metintas S; Ayhanci A; Metintas M
Cancer Biomark; 2023; 38(1):111-120. PubMed ID: 37545218
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
